WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H300165
CAS#: 62357-86-2 (acetate trihydrate)
Description: Desmopressin acetate is a synthetic replacement for vasopressin, the hormone that reduces urine production. It may be taken nasally, intravenously, or as a tablet. Doctors prescribe Desmopressin most frequently for treatment of diabetes insipidus or nocturnal enuresis. Desmopressin (1-desamino-8-D-arginine vasopressin) is a modified form of the normal human hormone arginine vasopressin, a peptide containing nine amino acids. Medical use of Desmopressin acetate includes: (a) bed wetting; (b) nighttime urination; (c) clotting disorders; (d) diabetes insipidus.
Hodoodo Cat#: H300165
Name: Desmopressin acetate trihydrate
CAS#: 62357-86-2 (acetate trihydrate)
Chemical Formula: C48H74N14O17S2
Exact Mass: 0.00
Molecular Weight: 1,189.320
Elemental Analysis: C, 48.72; H, 6.30; N, 16.57; O, 22.99; S, 5.42
Related CAS #: 62357-86-2 (acetate trihydrate) 69-25-0 (free base) 62288-83-9 (acetate) 16679-58-6 (free base) 16679-58-6 (free base)
Synonym: Adiuretin; Deamino Arginine Vasopressin; Desmogalen; Vasopressin 1-Desamino-8-arginine; trade names: DDAVP, DesmoMelt, Minirin, Minirin Melt, Octim, Stimate; Nocutil. Pubchem ID64759
IUPAC/Chemical Name: (S)-1-((4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-N-((R)-1-((2-amino-2-oxoethyl)amino)-5-guanidino-1-oxopentan-2-yl)pyrrolidine-2-carboxamide acetate trihydrate
InChi Key: YNKFCNRZZPFMEX-XHPDKPNGSA-N
InChi Code: InChI=1S/C46H64N14O12S2.C2H4O2.3H2O/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25;1-2(3)4;;;/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52);1H3,(H,3,4);3*1H2/t28-,29+,30+,31+,32+,33+,34+;;;;/m1..../s1
SMILES Code: O=C([C@H]1N(C([C@@H](NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)N4)=O)=O)=O)=O)CSSCCC4=O)=O)CCC1)N[C@H](CCCNC(N)=N)C(NCC(N)=O)=O.CC(O)=O.[H]O[H].[H]O[H].[H]O[H]
Appearance: white to light yellow crystal
Purity: >99% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in water or DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 62357-86-2 (Desmopressin acetate trihydrate); 62288-83-9 (Desmopressin acetate); 16679-58-6 (Desmopressin free base); 16789-98-3 (Desmopressin diacetate). Note: The drug API approved by FDA is Desmopressin acetate trihydrate, which CAS# is 62357-86-2 with Chemical Formula: C48H74N14O17S2 and Molecular Weight: 1183.31. Other forms of Desmopressin: Desmopressin (not FDA approved drug API) CAS# 16679-58-6 (desmopressin); Chemical Formula: C47H64N12O13S2 Exact Mass: 1068.41572; Molecular Weight: 1069.21 Elemental Analysis: C, 52.80; H, 6.03; N, 15.72; O, 19.45; S, 6.00 Desmopressin Acetate (not FDA approved drug API) CAS#62288-83-9 (desmopressin acetate); Chemical Formula: C49H68N12O15S2 Molecular Weight: 1129.26 Elemental Analysis: C, 52.12; H, 6.07; N, 14.88; O, 21.25; S, 5.68 Desmopressin diacetate (not FDA approved drug API) CAS#16789-98-3 (desmopressin diacetate) Chemical Formula: C50H72N14O16S2; Molecular Weight: 1189.32 Elemental Analysis: C, 50.49; H, 6.10; N, 16.49; O, 21.52; S, 5.39 Mode of action: Desmopressin works by limiting the amount of water that is eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of factor VIII from endothelial cells due to stimulation of the V1a receptor. Desmopressin is degraded more slowly than recombinant vasopressin, and requires less frequent administration. In addition, it has little effect on blood pressure, while vasopressin may cause arterial hypertension. [source: http://en.wikipedia.org/wiki/Desmopressin]. INDICATIONS: Central Diabetes Insipidus: DDAVP Tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to DDAVP can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis: DDAVP Tablets are indicated for the management of primary nocturnal enuresis. DDAVP may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. [source: http://www.rxlist.com/ddavp-drug.htm].
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Soluble in in water | 0.0 | 100.00 |
The following data is based on the product molecular weight 1,189.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Alford N, Hashim H. Desmopressin acetate the first sublingual tablet to treat nocturia due to nocturnal polyuria. Expert Rev Clin Pharmacol. 2021 Aug;14(8):939-954. doi: 10.1080/17512433.2021.1931122. Epub 2021 Jun 14. PMID: 33993824.
2: Cohn JA, Kowalik CG, Reynolds WS, Kaufman MR, Milam DF, Dmochowski RR, Wein AJ. Desmopressin acetate nasal spray for adults with nocturia. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1281-1293. doi: 10.1080/17512433.2017.1394185. Epub 2017 Oct 30. PMID: 29048257.
3: Karanth L, Barua A, Kanagasabai S, Nair NS. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009824. doi: 10.1002/14651858.CD009824.pub2. Update in: Cochrane Database Syst Rev. 2015;(9):CD009824. PMID: 23633378.
4: Karanth L, Barua A, Kanagasabai S, Nair S. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database Syst Rev. 2015 Sep 9;(9):CD009824. doi: 10.1002/14651858.CD009824.pub3. Update in: Cochrane Database Syst Rev. 2019 Feb 13;2:CD009824. PMID: 26350784.
5: Wang Q, Alshayyah R, Yang B. The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis. Low Urin Tract Symptoms. 2022 May;14(3):155-162. doi: 10.1111/luts.12423. Epub 2022 Jan 16. PMID: 35034423.
6: Moffatt ME, Harlos S, Kirshen AJ, Burd L. Desmopressin acetate and nocturnal enuresis: how much do we know? Pediatrics. 1993 Sep;92(3):420-5. PMID: 8361796.
7: Galati P, Archer T, Jolly R, Sullivant A, Wills R, Lathan P. Effects of desmopressin acetate administration in healthy dogs receiving prednisolone. J Vet Intern Med. 2021 Sep;35(5):2271-2276. doi: 10.1111/jvim.16250. Epub 2021 Aug 27. PMID: 34448503; PMCID: PMC8478070.
8: Sattari SA, Shahoori A, Shahbazian H, Sabetnia L, Aref A, Sattari AR, Ghorbani A. Desmopressin Acetate in Percutaneous Ultrasound-Guided Native Kidney Biopsy in Patients with Reduced Kidney Function: A Double-Blind Randomized Controlled Trial. Iran J Kidney Dis. 2022 Jul;16(4):238-245. PMID: 35962638.
9: Richardson DW, Robinson AG. Desmopressin. Ann Intern Med. 1985 Aug;103(2):228-39. doi: 10.7326/0003-4819-103-2-228. PMID: 3893256.
10: Lim CC, Tan HZ, Tan CS, Healy H, Choo J, Franca Gois PH. Desmopressin acetate to prevent bleeding in percutaneous kidney biopsy: a systematic review. Intern Med J. 2021 Apr;51(4):571-579. doi: 10.1111/imj.14774. PMID: 32040251.
11: Kasper CK. Desmopressin acetate (DDAVP). Good news. JAMA. 1984 May 18;251(19):2564-5. PMID: 6609247.
12: Wang LC, Hu YF, Chen L, Xing R, Lin XF, Kou QY. Desmopressin acetate decreases blood loss in patients with massive hemorrhage undergoing gastrointestinal surgery. Turk J Gastroenterol. 2020 Jun;31(6):474-481. doi: 10.5152/tjg.2020.19021. PMID: 32721919; PMCID: PMC7433999.
13: Temeck BK, Bachenheimer LC, Katz NM, Coughlin SS, Wallace RB. Desmopressin acetate in cardiac surgery: a double-blind, randomized study. South Med J. 1994 Jun;87(6):611-5. doi: 10.1097/00007611-199406000-00006. PMID: 8202769.
14: McManus J, Ferreira J, Jones GM, Smetana KS, Smith Condeni M, Berger K, Witenko C, Smotherman C, Gautam S, Pizzi MA, Erdman MJ. Effect of desmopressin acetate on acute spontaneous intracranial hemorrhage in patients on antiplatelet therapy. J Neurol Sci. 2022 Mar 15;434:120142. doi: 10.1016/j.jns.2022.120142. Epub 2022 Jan 6. PMID: 35081458.
15: Hayashi M. [Pharmacological and clinical profile of desmopressin acetate hydrate (MINIRIN Melt(®))]. Nihon Yakurigaku Zasshi. 2013 Mar;141(3):169-74. Japanese. doi: 10.1254/fpj.141.169. PMID: 23470483.
16: Vance DA. Desmopressin acetate. J Post Anesth Nurs. 1988 Feb;3(1):65-6. PMID: 3351781.
17: Manno C, Bonifati C, Torres DD, Campobasso N, Schena FP. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011 Jun;57(6):850-5. doi: 10.1053/j.ajkd.2010.12.019. Epub 2011 Feb 26. PMID: 21354681.
18: Smith RC. Desmopressin acetate in postoperative bleeding. DICP. 1990 May;24(5):475-6. PMID: 2188433.
19: David JL. Desmopressin and hemostasis. Regul Pept. 1993 Apr 29;45(1-2):311-7. doi: 10.1016/0167-0115(93)90227-y. PMID: 8511363.
20: Mansouritorghabeh H, Shirdel A. Desmopressin acetate as a haemostatic elevator in individuals with combined deficiency of factors V and VIII: a clinical trial. J Thromb Haemost. 2016 Feb;14(2):336-9. doi: 10.1111/jth.13207. Epub 2016 Jan 30. PMID: 26599105.
